FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 3 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence ESMO Calls for Cancer to Remain a Flagship Priority in the Next EU Budget MOST POPULAR Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer October 27, 2021 FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas January 20, 2021 Embryos in the Womb Can Get Gene Mutations That Lead to... April 28, 2022 Load more HOT NEWS Teen’s Innovative “SMART Armour” Protects Breast Cancer Patients from Radiation Breaking News: The Healthcare Marketplace Re-opens TODAY! Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality...
